Holsts laboratory played a central role in characterizing the active intestinal form of GLP-1, demonstrating its therapeutic potential in diabetes, as well as obesity treatment, and developing early drug analogs
Another important aspect is the cost and accessibility of the medication
Meet our doctors Last reviewed: 19 Jun 2026 Sources Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity, Diabetes, Obesity and Metabolism, [accessed 14 January 2026] Transdermal drug delivery: overcoming the skin's barrier function, Europe PMC [accessed 14 January 2026] (D) Routes of delivery: Case studies: (6) Transdermal delivery of peptides and proteins, Advanced Drug Delivery Reviews, [accessed 14 January 2026] Semaglutide for the treatment of overweight and obesity: A review, Diabetes, Obesity and Metabolism, [accessed 14 January 2026] Medicines and Healthcare products Regulatory Agency (MHRA), GOV.UK, [accessed 14 January 2026]
START YOUR BASELINE Most of what we write about here shows up in your blood work
With this triple action, early trials have shown, this GLP-3 to be even more effective than the currently available weight-loss medications
